Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2E69K
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Diversity"
DOI: 10.1007/s11030-020-10179-y
Abstract: Abstract The E69K mutation is one of the most frequent protein tyrosine phosphatase-2 (SHP2) mutations in leukemia, and it can cause the increase in the protein activity. Recent studies have shown that the E69K mutation… read more here.
Keywords: shp2; drug shp099; shp099 inhibiting; allosteric drug ... See more keywords
Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion.
Sign Up to like & getrecommendations! Published in 2022 at "ACS nano"
DOI: 10.1021/acsnano.2c03311
Abstract: Whereas adoptive T cell therapy has been extensively studied for cancer treatment, the response is still limited primarily due to immune dysfunction related to poor cell engraftment, tumor infiltration and engagement, and lack of a… read more here.
Keywords: shp099; cell; cell therapy; adoptive cell ... See more keywords